Publications
5674 Results
- Journal / Conference
- Blood 132:2927; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0816
Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling of SWOG S0816 with receiver operating characteristic analysis
- Journal / Conference
- Blood 132:309; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), oral
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10701
A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)
- Journal / Conference
- Blood 132:1386; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), accepted, poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106
Event-free Survival as a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-level Analysis of Multiple Randomized Trials (Alliance A151614)
- Journal / Conference
- Blood 132:1403; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1203
Predicting Non-Fatal Toxicities with 7+3 Induction Chemotherapy in Adult Acute Myeloid Leukemia: Analysis of SWOG Trial S1203
- Journal / Conference
- Blood 132:1992; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 with Long-Term Follow Up
- Journal / Conference
- Blood 132:437; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), accepted, oral/plenary
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2906
Prospective Study of Minimal Residual Disease (MRD) Status and Outcome After Complete Remission (CR) Following Intensive Remission Induction Therapy in Older Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years
- Journal / Conference
- Blood 132:3995American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2906
FLT3-ITD Mutations Are Prevalent in Older Adults with Acute Myeloid Leukemia (AML) and Significantly Impact Outcome After Intensive Therapy: Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age > 60 Years
- Journal / Conference
- Blood 132:435; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA)
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10603
Prognostic impact of insertion site in acute myeloid leukemia with FLT3 internal tandem duplication: results from the RATIFY study (Alliance)
- Journal / Conference
- Blood 132:1534; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10603
Comprehensive molecular profiling of FLT3-mutated acute myeloid leukemia (AML) patients treated within the RATIFY trial
- Journal / Conference
- Blood 132:2668; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10603